The CFX Opus 96 Dx System and the CFX Opus 384 Dx Real-Time PCR Systems Offer Accurate and Precise Quantification to Improve IVD Assay Development and Diagnostic Testing. Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a worldwide leader of life science research and scientific diagnostic products, today announced the launch of the CFX ™ Opus 96 Dx System and the CFX ™ Opus 384 Dx System, real-time PCR detection systems that have been listed with the U.S. Food and Drug Administration (FDA) for IVD screening and that meet the CE-IVD requirement for IVD use in Europe. The CFX Opus 96 Dx System and the CFX Opus 384 Dx System are the latest additions to Bio-Rads portfolio of real-time PCR instruments. The CFX Opus 96 Dx Real-Time PCR System and the CFX Opus 384 Dx Real-Time PCR System are open systems that can multiplex up to 5 targets to supply effective IVD assay advancement and screening.
The CFX Opus 96 Dx System and the CFX Opus 384 Dx Real-Time PCR Systems Offer Accurate and Precise Quantification to Improve IVD Assay Development and Diagnostic Testing. Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research study and medical diagnostic products, today announced the launch of the CFX ™ Opus 96 Dx System and the CFX ™ Opus 384 Dx System, real-time PCR detection systems that have been listed with the U.S. Food and Drug Administration (FDA) for IVD screening which fulfill the CE-IVD requirement for IVD use in Europe. Both systems are likewise signed up with regulative bodies for IVD use in Singapore and Canada. The CFX Opus 96 Dx System and the CFX Opus 384 Dx System are the latest additions to Bio-Rads portfolio of real-time PCR instruments. The systems offer precise and accurate metrology to improve assay development and workflow performances and efficiency for diagnostic screening and research. The CFX Opus 96 Dx Real-Time PCR System and the CFX Opus 384 Dx Real-Time PCR System are open systems that can multiplex up to 5 targets to supply effective IVD assay development and screening. The systems provide accurate quantification, improved thermal cycler efficiency, and the systems offer user friendly desktop management and analysis software with integrated security features. “We continue to see an increasing need for real-time PCR systems that offer more efficient workflows and improved data management and analysis that meets regulatory requirements in IVD assay development and testing, and were happy to present the CFX Opus Dx Detection Systems to meet these needs,” said Steven Blakely, Director for Gene Expression and Software Technology, Bio-Rad. “Both systems are robust and protected platforms that leverage Bio-Rads enduring competence in genomic tools to much better serve both research and scientific diagnostic markets,” he added. About Bio-RadBio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a worldwide leader in developing, producing, and marketing a broad series of ingenious products for the life science research study and medical diagnostic markets. With a concentrate on quality and client service for over 65 years, our products advance the discovery process and enhance health care. Our customers are university and research study organizations, healthcare facilities, public health and industrial labs, biotechnology and pharmaceutical companies, along with used laboratories that include food security and ecological quality. Established in 1952, Bio-Rad is based in Hercules, California, and has a worldwide network of operations with around 7,800 staff members worldwide. Bio-Rad had revenues surpassing $2.5 billion in 2020. To find out more, please see bio-rad. com. This release might be considered to contain specific forward-looking declarations within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements consist of, without constraint, statements we make concerning our expectations about our products. Positive declarations typically can be determined by the use of positive terms such as “plan”, “believe,” “anticipate,” “prepare for,” “may,” “will,” “intend,” “estimate,” “continue,” or comparable expressions or the unfavorable of those terms or expressions, although not all positive statements include these words. Such declarations involve unpredictabilities and threats, which could trigger actual outcomes to differ materially from those revealed in or suggested by the forward-looking statements. These risks and uncertainties include the duration and intensity of the COVID-19 pandemic, our ability to establish and market enhanced or brand-new items, our ability to contend successfully, global legal and regulatory risks, and item quality and liability issues. For more details regarding our uncertainties and threats, please refer to the “Risk Factors” and “Managements Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rads public reports submitted with the Securities and Exchange Commission, including our latest Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to put unnecessary dependence on positive declarations, which show an analysis just and speak just as of the date hereof. We disclaim any obligation to upgrade these forward-looking declarations.
